Evidence map›Paper›PMID 41420206›Full record

Observational studyBMC cardiovascular disorders2025

The impact of heart failure and bleeding risk on clinical outcomes in patients after percutaneous coronary intervention.

Yoshiyuki Yazaki, Yoshihisa Nakagawa, Ken Kozuma, Raisuke Iijima, Anna Tsutsui, Yoshitaka Murakami, Masayuki Fukuzawa, Satoru Abe, Go Kato, Hidehiko Hara and 1 more

Abstract readObservational StudyMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshiyuki YazakiDivision of Cardiovascular Medicine, Toho University Ohashi Medical Centre, 2-22-36, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.
Yoshihisa NakagawaDepartment of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan.
Ken KozumaDivision of Cardiology, Department of Internal Medicine, Teikyo University, Tokyo, Japan.
Raisuke IijimaDivision of Cardiovascular Medicine, Toho University Ohashi Medical Centre, 2-22-36, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.
Anna TsutsuiDepartment of Medical Statistics, School of Medicine, Toho University, Tokyo, Japan.
Yoshitaka MurakamiDepartment of Medical Statistics, School of Medicine, Toho University, Tokyo, Japan.
Masayuki FukuzawaPrimary Medical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Satoru AbePrimary Medical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Go KatoPrimary Medical Science Department, Daiichi Sankyo Co., Ltd, Tokyo, Japan.
Hidehiko HaraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Centre, 2-22-36, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.
Masato NakamuraDivision of Cardiovascular Medicine, Toho University Ohashi Medical Centre, 2-22-36, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan. masato@oha.toho-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn recent years, revascularization for ischaemic heart failure (HF) has received increasing attention, and percutaneous coronary intervention (PCI) has been positioned as a high-risk procedure. However, the risk of major bleeding and major adverse cardiac and cerebrovascular events (MACCE) after PCI for patients with ischaemic HF has not been adequately evaluated.

methodsHF patients were selected from the PENDULUM (Platelet rEactivity in patieNts with DrUg eLUting stent and balancing risk of bleeding and ischaemic event) registry to compare the efficacy and safety of PCI in HF and non-HF patients. In addition, the impact of high bleeding risk (HBR) defined as BARC 3 and 5 was evaluated in these patients.

resultsA total of 6266 patients were included; 16% (n = 1006) had a history of HF at enrolment. Patients with HF showed a higher MACCE rate than those without HF (18.4% versus 7.7%; adjusted hazard ratio [HR] = 1.59, 95%CI, 1.30–1.93; p < 0.001) and a significant difference in major bleeding (9.3% versus 3.3%; adjusted HR = 1.74, 95%CI, 1.30–2.33; p < 0.001). HBR was significantly more associated with the MACCE and major bleeding rates than non-HBR, regardless of HF status (adjusted HR = 2.93, 95% CI: 2.33–3.69, p < 0.001, p for interaction = 0.913, adjusted HR = 2.67, 95% CI: 1.89–3.76, p < 0.001, p for interaction = 0.465, respectively).

conclusionsAfter contemporary PCI, HF and HBR were independently associated with a higher risk of MACCE and bleeding. HF patients after PCI require more careful management to improve prognosis, particularly with HBR factors.

Indexed as

Coronary Artery DiseaseHeart FailureHemorrhagePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAgedDrug-Eluting StentsFemaleHumansMaleMiddle AgedRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomePlatelet Aggregation InhibitorsHeart failureHigh bleeding riskMajor adverse cardiac and cerebrovascular eventsMajor bleedingPercutaneous coronary intervention

Identifiers

PMID41420206
PMCPMC12831353

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.